Infection risk in Rheumatoid Arthritis and Spondyloarthropathy patients under treatment with DMARDs, Corticosteroids and TNF-α antagonists

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Germano, Valentina ^a   Cattaruzza, Maria S ^b   Osborn, John ^b   Tarantino, Aurora ^a,c   Di Rosa, Roberta ^a   Salemi, Simonetta ^a   D'Amelio, Raffaele ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c National Health Service   (Italy)

Author keywords

anti TNF ; Corticosteroids; DMARDs; Infection risk; Rheumatoid Arthritis; Spondyloarthropathy

Indexed keywords

CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ISONIAZID; METHOTREXATE; PEGINTERFERON; PREDNISONE; RIBAVIRIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DRUG SAFETY; FEMALE; GENDER; HUMAN; INFECTION RISK; INFLUENZA VACCINATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OBSERVATIONAL STUDY; OUTPATIENT; PATIENT CODING; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SKIN INFECTION; SOFT TISSUE INFECTION; SPONDYLOARTHROPATHY; STATISTICAL MODEL;

ADRENAL CORTEX HORMONES; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COMMUNICABLE DISEASES; DEMOGRAPHY; FEMALE; HUMANS; INFLUENZA VACCINES; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RISK FACTORS; SPONDYLARTHROPATHIES; TUMOR NECROSIS FACTOR-ALPHA; VACCINATION;

EID: 84899150062     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-12-77     Document Type: Article

References (70)

1. Myllykangas-Luosujarvi R, Aho K, Kautiainen H, Isomaki H. Shortening of life span and causes of excess mortality in a population-based series of subjects with rheumatoid arthritis. Clin Exp Rheumatol 1995, 13:149-153.
2. Gonzalez A, Kremers MH, Crowson CS, Nicola PJ, Davis JM, Therneau TM, Roger VL, Gabriel SE. The widening mortality gap, between rheumatoid arthritis patients and the general population. Arthritis Rheum 2007, 56:3583-3587. 10.1002/art.22979, 17968923.
3. Vanderbroucke JP, Hazevoet HM, Cats A. Survival and cause of death in rheumatoid arthritis: a 25-year prospective follow-up. J Rheumatol 1984, 11:158-161.
4. Van Albada-Kuipers GA, Linthorst J, Peeters EA, Breedveld FC, Dijkmans BA, Hermans J, Vandenbroucke JP, Cats A. Frequency of infection among patients with rheumatoid arthritis versus patients with osteoarthritis or soft tissue rheumatism. Arthritis Rheum 1988, 31:667-671. 10.1002/art.1780310513, 3259884.
5. Baum J. Infection in rheumatoid arthritis. Arthritis Rheum 1971, 14:135-137. 10.1002/art.1780140119, 5542366.
6. Vandenbroucke JP, Kaaks R, Valkenburg HA, Boersma JW, Cats A, Festen JJ, Hartman AP, Huber-Bruning O, Rasker JJ, Weber J. Frequency of infections among rheumatoid arthritis patients, before and after disease onset. Arthritis Rheum 1987, 30:810-813. 10.1002/art.1780300711, 3619963.
7. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002, 46:2287-2293. 10.1002/art.10524, 12355475.
8. Askling J, Dixon WG. The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol 2008, 20:138-144. 10.1097/BOR.0b013e3282f4b392, 18349742.
9. Lacaille D, Guh DP, Abrahamowicz M, Anis AH, Esdaile JM. Use of non biologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum (Arthritis Care Res) 2008, 59:1074-1081.
10. Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, Griffin MR, Herrinton LJ, Liu L, Ouellet-Hellstrom R, Patkar NM, Solomon DH, Lewis JD, Xie F, Saag KG, Curtis JR. Initiation of Tumor Necrosis Factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011, 306:2331-2339. 3428224, 22056398.
11. Fouqué-Aubert A, Jette-Paulin L, Combescure C, Basch A, Tebib J, Gossec L. Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials. Ann Rheum Dis 2010, 69:1756-1761. 10.1136/ard.2008.098822, 19640854.
12. Winthrop KL. Infectious and biologic therapy in Rheumatoid Arthritis. Our changing understanding of risk and prevention. Rheum Dis Clin N Am 2012, 38:727-745.
13. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in Rheumatoid Arthritis. Arthritis Rheum 2002, 49:2294-2300.
14. Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford) 2007, 46:1157-1160. 10.1093/rheumatology/kem076, 17478469.
15. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000, 343:1594-1602. 10.1056/NEJM200011303432202, 11096166.
16. Kareskog L, van der Heijde D, De Jager JP, Gough A, Kalden J, Malaise M, Martín Mola E, Pavelka K, Sany J, Settas L, Wajdula J, Pedersen R, Fatenejad S, Sanda M. TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004, 363:675-681. 10.1016/S0140-6736(04)15640-7, 15001324.
17. Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG. Long-term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4-year extended study. Ann Rheum Dis 2005, 65:753-759. 1798163, 16308341.
18. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295:2275-2285. 10.1001/jama.295.19.2275, 16705109.
19. Dixon WG, Watson K, Lunt M. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy. Results From the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006, 54:2368-2376. 10.1002/art.21978, 16868999.
20. Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2010, 39:327-346. 10.1016/j.semarthrit.2008.10.002, 19117595.
21. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG. The American Rheumatism. Association 1987 Revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
22. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973, 3:55-78. 10.1016/0049-0172(73)90035-8, 4581554.
23. Goie The HS, Steven MM, van der Linden SM, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a comparison of the Rome, New York and modified New York criteria in patients with a positive clinical history screening test for ankylosing spondylitis. Br J Rheumatol 1985, 24:242-249. 10.1093/rheumatology/24.3.242, 3160423.
24. British Thoracic Society Standards of care Committee BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF- α treatment. Thorax 2005, 60:800-805. 1747200, 16055611, British Thoracic Society Standards of care Committee.
25. Gómez-Reino JJ, Carmona L, Descalzo AM Biobadaser Group Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007, 57:756-761. 10.1002/art.22768, 17530674, Biobadaser Group.
26. Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, Burra P, Caraceni P, Daniele B, Di Marco V, Fabrizi F, Fagiuoli S, Grossi P, Lampertico P, Meliconi R, Mangia A, Puoti M, Raimondo G, Smedile A For the Italian Association for the Study of Liver (AISF) Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007, 39:397-408. 10.1016/j.dld.2006.12.017, 17382608, For the Italian Association for the Study of Liver (AISF).
27. Viganò M, Degasperi E, Aghemo A, Lampertico P, Colombo M. Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. Expert Opin Biol Ther 2012, 12:193-207. 10.1517/14712598.2012.646986, 22188392.
28. Ferri C, Ferraccioli G, Ferrari D, Galeazzi M, Lapadula G, Montecucco C, Triolo G, Valentini G Valesini. GISEA Group Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol 2008, 35:1944-1949. Valesini. GISEA Group.
29. Pregliasco F, Puzelli S, Mensi C, Anselmi G, Marinello R, Tanzi ML, Affinito C, Zambon MC, Donatelli I The Collaborative Group Influchild Influenza virological surveillance in children: the use of the Quickvue rapid diagnostic test. J Med Virol 2004, 73:269-273. 10.1002/jmv.20086, 15122803, The Collaborative Group Influchild.
30. Au K, Reed G, Curtis JR, Kremer JM, Greenberg JD, Strand V, Furst DE CORRONA investigators High disease activity is associated with an increased risk of infection in patient with rheumatoid arthritis. Ann Rheum Dis 2011, 70:785-791. 10.1136/ard.2010.128637, 21288960, CORRONA investigators.
31. Salliot C, Gossec L, Ruyssen-Witrand A, Luc M, Duclos M, Guignard S, Dougados M. Infections during tumor necrosis factor-α-blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology (Oxford) 2007, 46:327-334.
32. Listing J, Strangfeld A, Kary S, Rau R, Von Hinueber U, Stoyanova-Scholz M, Gromnica-Ihle E, Antoni C, Herzer P, Kekow J, Schneider M, Zink A. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005, 52:3403-3412. 10.1002/art.21386, 16255017.
33. Favalli EG, Desiati F, Atzeni F, Sarzi-Puttini P, Caporali R, Pallavicini FB, Gorla R, Filippini M, Marchesoni A. Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients. Autoimmun Rev 2009, 8:266-273. 10.1016/j.autrev.2008.11.002, 19022409.
34. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ. A trial of Etanercept, a recombinant Tumor necrosis Factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999, 340:253-259. 10.1056/NEJM199901283400401, 9920948.
35. Galloway JB, Mercer LK, Moseley A, Dixon WG, Ustianowski AP, Helbert M, Watson KD, Lunt M, Hyrich KL, Symmons DP. Risk of skin and soft tissue infections(including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2013, 72:229-234. 10.1136/annrheumdis-2011-201108, 3595979, 22532633.
36. Groves RW, Allen MH, Ross EL, Barker JN, MacDonald DM. Tumour necrosis factor alpha is pro-inflammatory in normal human skin and modulates cutaneous adhesion molecule expression. Br J Dermatol 1995, 132:345-352. 10.1111/j.1365-2133.1995.tb08666.x, 7536438.
37. Vestergaard C, Johansen C, Otkjaer K, Deleuran M, Iversen L. Tumor necrosis factor induced CTACK/CCL27 (cutaneous T cell-attracting chemokine) production in keratinocytes is controlled by nuclear factor kappa B. Cytokine 2005, 29:49-55. 10.1016/j.cyto.2004.09.008, 15598438.
38. Griffiths CE, Dearman RJ, Cumberbatch M, Kimber I. Cytokines and Langerhans cell mobilisation in mouse and man. Cytokine 2005, 32:67-70. 10.1016/j.cyto.2005.07.011, 16153855.
39. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor-neutralizing agent. N Engl J Med 2001, 345:1098-1104. 10.1056/NEJMoa011110, 11596589.
40. Caporali R, Bobbio-Pallavicini F, Atzeni F, Sakellariou G, Caprioli M, Montecucco C, Sarzi-Puttini P. Safety of Tumor Necrosis Factor Blockers in Hepatitis B Virus Occult Carriers (Hepatitis B Surface Antigen Negative/Anti-Hepatitis B Core Antigen Positive) With Rheumatic Diseases. Arthritis Care Res 2010, 62:749-754.
41. Brunasso AMG, Puntoni M, Gulia A, Massone C. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatology 2011, 50:1700-1711. 10.1093/rheumatology/ker190, 21690185.
42. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, Watson KD, Lunt M, Symmons DP BSRBR Control Centre Consortium; British Society for Rheumatology Biologics Register Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2011, 50:124-131. 10.1093/rheumatology/keq242, 3105607, 20675706, BSRBR Control Centre Consortium; British Society for Rheumatology Biologics Register.
43. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, Coster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapaa-Dahlqvist S, Saxne T, Van Vollenhoven RF, Klareskog L. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007, 66:1339-1344. 10.1136/ard.2006.062760, 1994293, 17261532.
44. Hooton TM. Clinical practice. Uncomplicated urinary tract infection. N Engl J Med 2012, 366:1028-1037. 10.1056/NEJMcp1104429, 22417256.
45. Coyne P, Hamilton J, Haycock C, Saravanan V, Coulson E, Kelly CA. Acute lower respiratory tract infections in patients with rheumatoid arthritis. J Rheumatol 2007, 34:1832-1836.
46. Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology 2013, 53:53-61.
47. Kanterman J, Sade-Feldman M, Baniyash M. New insights into chronic inflammation-induced immunosuppression. Semin Cancer Biol 2012, 22:307-318. 10.1016/j.semcancer.2012.02.008, 22387003.
48. Dixon WG, Kezouh A, Bernatsky S, Suissa S. The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study. Ann Rheum Dis 2011, 70:956-960. 10.1136/ard.2010.144741, 3086054, 21285116.
49. Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. Am Acad Dermatol 2011, 64:1035-1050.
50. Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE, Levin R, Solomon DH. Anti-tumour necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007, 56:1754-1764. 10.1002/art.22600, 17530704.
51. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 2006, 54:628-634. 10.1002/art.21568, 16447241.
52. Atzeni F, Sarzi-Puttini P, Botsios C, Carletto A, Cipriani P, Favalli EG, Frati E, Foschi V, Gasparini S, Giardina A, Gremese E, Iannone F, Sebastiani M, Ziglioli T, Biasi D, Ferri C, Galeazzi M, Gerli R, Giacomelli R, Gorla R, Govoni M, Lapadula G, Marchesoni A, Salaffi F, Punzi L, Triolo G, Ferraccioli G. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev 2012, 12:225-229. 10.1016/j.autrev.2012.06.008, 22796281.
53. Strangfeld A, Eveslage M, Schneider M, Bergerhausen HJ, Klopsch T, Zink A, Listing J. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?. Ann Rheum Dis 2011, 70:1914-1920. 10.1136/ard.2011.151043, 3184240, 21791449.
54. Guenther BD, Sheppard CA, Tran P, Rozen R, Matthews RG, Ludwig ML. The structure and properties of methylenetetrahydrofolate reductase from Escherichia coli suggest how folate ameliorates human hyperhomocysteinemia. Nat Struct Biol 1999, 6:359-365. 10.1038/7594, 10201405.
55. Bronowicki JP, Abdelmouttaleb I, Peyrin-Biroulet L, Venard V, Khiri H, Chabi N, Amouzou EK, Barraud H, Halfon P, Sanni A, Bigard MA, Le Faou A, Guéant JL. Methylenetetrahydrofolate reductase 677 T allele protects against persistent HBV infection in West Africa. J Hepatol 2008, 48:532-539. 10.1016/j.jhep.2007.11.017, 18222012.
56. Fodil-Cornu N, Kozij N, Wu Q, Rozen R, Vidal SM. Methylenetetrahydrofolate reductase (MTHFR) deficiency enhances resistance against cytomegalovirus infection. Genes Immun 2009, 10:662-666. 10.1038/gene.2009.50, 19609317.
57. Lanza L, Scudeletti M, Puppo F, Bosco O, Peirano L, Filaci G, Fecarotta E, Vidali G, Indiveri F. Prednisone increases apoptosis in in vitro activated human peripheral blood T lymphocytes. Clin Exp Immunol 1996, 103:482-490. 2200357, 8608650.
58. DeRijk R, Michelson D, Karp B, Petrides J, Galliven E, Deuster P, Paciotti G, Gold PW, Sternberg EM. Exercise and Circadian Rhythm-Induced Variations in Plasma Cortisol Differentially Regulate Interleukin-1b (IL-1b), IL-6, and Tumor Necrosis Factor-a (TNFα) Production in Humans: High Sensitivity of TNFα and Resistance of IL-6. J Clin Endocrinol Metab 1997, 82:2182-2191.
59. Salemi S, Germano V, Picchianti Diamanti A, D'Amelio R. Role of antibody-secreting cells as early biomarkers of immune response to influenza vaccination in Rheumatoid arthritis patients treated with anti-TNFα agents. Int J Clin Rheumatol 2012, 7:155-158.
60. Miller AH, Pearce BD, Ruzek MC, Biron CA. Interactions between the hypothalamic-pituitary-adrenal axis and immune system during viral infection: pathways for environmental effects on disease expression. Handbook of Physiology. Section 7: The Endocrine System. New York, Oxford University Press, 2001, vol 4: Coping with the Environment: Neural and Endocrine Mechanisms 2001, 425-450. McEwen BS.
61. Gelfand EW. Intravenous Immune Globulin in Autoimmune and Inflammatory Diseases. N Engl J Med 2012, 367:2015-2025. 10.1056/NEJMra1009433, 23171098.
62. Kunisaki KM, Janoff EN. Influenza in Immunosuppressed Populations: A Review of Infection Frequency, Morbidity, Mortality, and Vaccine Responses. Lancet Infect Dis 2009, 9:493-504. 10.1016/S1473-3099(09)70175-6, 2775097, 19628174.
63. Beck CR, McKenzie BC, Hashim AB, Harris RC, Zanuzdana A, Agboado G, Orton E, Béchard-Evans L, Morgan G, Stevenson C, Weston R, Mukaigawara M, Enstone J, Augustine G, Butt M, Kim S, Puleston R, Dabke G, Howard R, O'Boyle J, O'Brien M, Ahyow L, Denness H, Farmer S, Figureroa J, Fisher P, Greaves F, Haroon M, Haroon S, Hird C, et al. Influenza vaccination for immunocompromised patients: systematic review and meta-analysis from a public health policy perspective. PLoS One 2011, 6:e29249. 10.1371/journal.pone.0029249, 3245259, 22216224.
64. Miller JB. Treatment of active herpes virus infections with influenza virus vaccine. Ann Allergy 1979, 42:295-305.
65. Saha S, Yoshida S, Ohba K, Matsui K, Matsuda T, Takeshita F, Umeda K, Tamura Y, Okuda K, Klinman D, Xin KQ, Okuda K. A fused gene of nucleoprotein (NP) and herpes simplex virus genes(VP22) induces highly protective immunity against different subtypes of influenza virus. Virology 2006, 354:48-57. 10.1016/j.virol.2006.04.015, 16945400.
66. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Scholte M, Scott DL, Sokka T, Valesini G, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69:964-975. 10.1136/ard.2009.126532, 2935329, 20444750.
67. Kirwan JR, Bijlsma JW, Boers M, Shea BJ. Effect of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 2007, CD006356.
68. Salemi S, D'Amelio R. Are anti-infectious vaccinations safe and effective in patients with autoimmunity?. Int Rev Immunol 2010, 29:270-314. 10.3109/08830185.2010.483028, 20521926.
69. Van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, Emery P, Geborek P, Ioannidis JP, Jayne DR, Kallenberg CG, Muller-Ladner U, Shoenfeld Y, Stojanovich L, Valesini G, Wulffraat NM, Bijl M. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011, 70:414-422. 10.1136/ard.2010.137216, 21131643.
70. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O'Dell J, Winthrop KL, Beukelman T, Bridges SL, Chatham WW, Paulus HE, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG. 2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken) 2012, 64:475-487. 10.1002/acr.21591, 3349440, 22563590.